• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于RNA干扰的非病毒药物递送系统的毒理基因组学:对小干扰RNA介导的基因沉默活性和特异性的潜在影响。

Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.

作者信息

Akhtar Saghir, Benter Ibrahim

机构信息

SA Pharma, Vesey Road 1, Sutton Coldfield, West Midlands, B73 5NP, United Kingdom.

出版信息

Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):164-82. doi: 10.1016/j.addr.2007.03.010. Epub 2007 Mar 21.

DOI:10.1016/j.addr.2007.03.010
PMID:17481774
Abstract

RNA interference (RNAi) is an evolutionary conserved cellular process for the regulation of gene expression. In mammalian cells, RNAi is induced via short (21-23 nt) duplexes of RNA, termed small interfering RNA (siRNA), that can elicit highly sequence-specific gene silencing. However, synthetic siRNA duplexes are polyanionic macromolecules that do not readily enter cells and typically require the use of a delivery vector for effective gene silencing in vitro and in vivo. Choice of delivery system is usually made on its ability to enhance cellular uptake of siRNA. However, recent gene expression profiling (toxicogenomics) studies have shown that separate from their effects on cellular uptake, delivery systems can also elicit wide ranging gene changes in target cells that may impact on the 'off-target' effects of siRNA. Furthermore, if delivery systems also alter the expression of genes targeted for silencing, then siRNA activity may be compromised or enhanced depending on whether the target gene is up-regulated or down-regulated respectively. Citing recent examples from the literature, this article therefore reviews the toxicogenomics of non-viral delivery systems and highlights the importance of understanding the genomic signature of siRNA delivery reagents in terms of their impact on gene silencing activity and specificity. Such information will be essential in the selection of optimally acting siRNA-delivery system combinations for the many applications of RNA interference.

摘要

RNA干扰(RNAi)是一种进化保守的细胞过程,用于调节基因表达。在哺乳动物细胞中,RNAi通过短(21 - 23个核苷酸)的RNA双链体诱导产生,称为小干扰RNA(siRNA),它能引发高度序列特异性的基因沉默。然而,合成的siRNA双链体是多阴离子大分子,不易进入细胞,通常需要使用递送载体才能在体外和体内实现有效的基因沉默。递送系统的选择通常基于其增强细胞摄取siRNA的能力。然而,最近的基因表达谱分析(毒理基因组学)研究表明,除了对细胞摄取的影响外,递送系统还能在靶细胞中引发广泛的基因变化,这可能会影响siRNA的“脱靶”效应。此外,如果递送系统还改变了靶向沉默基因的表达,那么siRNA的活性可能会受到损害或增强,这取决于靶基因是分别被上调还是下调。本文引用文献中的最新例子,综述了非病毒递送系统的毒理基因组学,并强调了了解siRNA递送试剂的基因组特征对其基因沉默活性和特异性影响的重要性。这些信息对于为RNA干扰的众多应用选择最佳作用的siRNA - 递送系统组合至关重要。

相似文献

1
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.用于RNA干扰的非病毒药物递送系统的毒理基因组学:对小干扰RNA介导的基因沉默活性和特异性的潜在影响。
Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):164-82. doi: 10.1016/j.addr.2007.03.010. Epub 2007 Mar 21.
2
Cationic lipids and polymers mediated vectors for delivery of siRNA.用于递送小干扰RNA的阳离子脂质和聚合物介导载体
J Control Release. 2007 Oct 18;123(1):1-10. doi: 10.1016/j.jconrel.2007.07.016. Epub 2007 Aug 7.
3
RNA interference (RNAi) in hematology.血液学中的RNA干扰(RNAi)。
Ann Hematol. 2004 Jan;83(1):1-8. doi: 10.1007/s00277-003-0759-1. Epub 2003 Oct 22.
4
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.非病毒载体介导的RNA干扰:其基因沉默特性及实现基于RNA干扰的基因治疗的重要因素。
Adv Drug Deliv Rev. 2009 Jul 25;61(9):760-6. doi: 10.1016/j.addr.2009.04.006. Epub 2009 Apr 20.
5
Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.小干扰RNA的脂质载体:与质粒DNA在制剂、细胞摄取及递送方面的差异
Biochemistry. 2004 Oct 26;43(42):13348-56. doi: 10.1021/bi048950a.
6
Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.体内通过RNA干扰(RNAi)实现基因沉默:基于直接应用小干扰RNA(siRNA)的策略。
J Biotechnol. 2006 Jun 25;124(1):12-25. doi: 10.1016/j.jbiotec.2005.12.003. Epub 2006 Jan 18.
7
RNAi in functional genomics.功能基因组学中的RNA干扰
Curr Opin Mol Ther. 2004 Apr;6(2):129-35.
8
siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.小干扰RNA:作为治疗药物的潜力——第二部分。递送方法。
Drug Discov Today. 2009 Sep;14(17-18):859-65. doi: 10.1016/j.drudis.2009.06.002. Epub 2009 Jun 21.
9
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.非病毒载体介导的小干扰RNA靶向递送:从近期进展中汲取的经验教训
Curr Opin Investig Drugs. 2008 Dec;9(12):1317-23.
10
Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics.阳离子纳米系统递送小干扰核糖核酸治疗药物:毒代基因组学重点
Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1347-62. doi: 10.1517/17425255.2010.518611. Epub 2010 Oct 7.

引用本文的文献

1
The potential role of cyclosporine A in cancer treatment: a comprehensive literature review.环孢素A在癌症治疗中的潜在作用:一项全面的文献综述。
Contemp Oncol (Pozn). 2024;28(4):271-282. doi: 10.5114/wo.2024.147009. Epub 2025 Jan 15.
2
Gelatin and lipidoid integrate to create to enhance siRNA delivery with low toxicity.明胶和类脂体相结合以增强小干扰RNA(siRNA)递送,且毒性较低。
Bioact Mater. 2024 Jul 23;40:557-570. doi: 10.1016/j.bioactmat.2024.06.008. eCollection 2024 Oct.
3
Inactivity-induced phrenic motor facilitation requires PKCζ activity within phrenic motor neurons.
不活动诱导的膈神经运动易化需要膈运动神经元内的 PKCζ 活性。
J Neurophysiol. 2024 Jun 1;131(6):1188-1199. doi: 10.1152/jn.00138.2024. Epub 2024 May 1.
4
Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment.通过小干扰RNA疗法重塑肿瘤免疫微环境以实现精准癌症治疗。
Asian J Pharm Sci. 2023 Sep;18(5):100852. doi: 10.1016/j.ajps.2023.100852. Epub 2023 Oct 10.
5
A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics.siRNA 治疗药物的内在毒性和传递介导毒性的整体分析。
Adv Drug Deliv Rev. 2023 Oct;201:115052. doi: 10.1016/j.addr.2023.115052. Epub 2023 Aug 9.
6
Mitigating Cardiotoxicity of Dendrimers: Angiotensin-(1-7) via Its Mas Receptor Ameliorates PAMAM-Induced Cardiac Dysfunction in the Isolated Mammalian Heart.减轻树枝状大分子的心脏毒性:血管紧张素-(1-7)通过其Mas受体改善聚酰胺-胺型树枝状大分子诱导的离体哺乳动物心脏功能障碍。
Pharmaceutics. 2022 Dec 1;14(12):2673. doi: 10.3390/pharmaceutics14122673.
7
Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis.基于非编码 RNA 治疗剂的靶向递呈在动脉粥样硬化中的最新进展。
Mol Ther. 2022 Oct 5;30(10):3118-3132. doi: 10.1016/j.ymthe.2022.07.018. Epub 2022 Aug 1.
8
Anti- RNAi-Based Onconanotherapeutics.基于抗RNA干扰的肿瘤治疗药物
Biomedicines. 2020 Dec 15;8(12):612. doi: 10.3390/biomedicines8120612.
9
Small interfering RNA for cancer treatment: overcoming hurdles in delivery.用于癌症治疗的小干扰RNA:克服递送障碍
Acta Pharm Sin B. 2020 Nov;10(11):2075-2109. doi: 10.1016/j.apsb.2020.10.005. Epub 2020 Oct 13.
10
RNA interference in glial cells for nerve injury treatment.用于神经损伤治疗的胶质细胞中的RNA干扰
J Tissue Eng. 2020 Jul 6;11:2041731420939224. doi: 10.1177/2041731420939224. eCollection 2020 Jan-Dec.